Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG4059 in Healthy Male Subjects
NCT04575818Phase 1Terminated
- Sponsor
- Galapagos NV
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG4059 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Galapagos NV. Primary endpoint: Treatment-emergent adverse events. Started Sep 2020; status: terminated.
02
Drugs
GLPG4059
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04575818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575818.